BLB&B Advisors’s iShares Biotechnology ETF IBB Stock Holding History

BLB&B Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,711	Closed	-$235K	–	278
2024 Q1	$235K	Buy	+1,711	New	+$234K	0.01%	254

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

BLB&B Advisors's IBB Position: Q2 2024 in Review

BLB&B Advisors sold out of iShares Biotechnology ETF (IBB) in Q2 2024, closing a stake of 1,711 shares — an estimated $235K sold.

BLB&B Advisors first reported a position in IBB in Q1 2024 and held it in 1 quarter. The position peaked at $235K in Q1 2024. 896 funds tracked by Wall St. Rank hold IBB as of Q2 2024.

BLB&B Advisors reported no remaining iShares Biotechnology ETF position as of Q2 2024 after selling out during the quarter.
BLB&B Advisors sold 1,711 iShares Biotechnology ETF shares in Q2 2024, an estimated $235K.
BLB&B Advisors first reported a position in iShares Biotechnology ETF in Q1 2024 and held it in 1 quarter.
BLB&B Advisors's iShares Biotechnology ETF position peaked at $235K in Q1 2024.
896 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2024.

Based on BLB&B Advisors's 13F filing for Q2 2024, filed 26 Jul 2024.